Immunology & Nutrition
Critical Review · February 2026

Vitamin D & Infection Susceptibility

A mechanistic deep-dive into the "Sunshine Vitamin" as immunomodulator. From photolysis in the skin to cathelicidin in the macrophage — does correcting deficiency truly reduce infection risk? We trace every step of the biology and weigh the clinical evidence.

8 Mechanisms Illustrated Evidence-Based Meta-Analyses
Step 1

Photolysis in the Skin

Vitamin D₃ production begins when UVB radiation (290–315 nm) cleaves the B-ring of 7-dehydrocholesterol (7-DHC) in basal keratinocytes — a reaction that has powered vertebrate immunity for 500 million years. The photolysis product (pre-D₃) thermally isomerizes to D₃ over ~3 days, then enters the dermal capillaries bound to vitamin D-binding protein (DBP) for transport to the liver.

Synthesis Pathway

☀️ UVB (290–315 nm) Solar radiation
Skin (7-DHC) Basal keratinocytes
pre-D₃ B-ring cleavage
D₃ (Cholecalciferol) Thermal isomerization ~3 days
Blood (DBP-bound) Dermal capillaries
🫀 Liver Next activation step

🌍 Latitude Matters

Above ~35°N latitude, UVB intensity drops below the threshold for D₃ synthesis during winter months. This creates a seasonal "vitamin D winter" lasting 4–6 months at high latitudes.

🧬 Melanin as Filter

Melanin competes with 7-DHC for UVB photons. Individuals with darker skin (Fitzpatrick V–VI) require 3–5× longer sun exposure to produce equivalent D₃ — a major factor in health disparities.

🍽️ Dietary Limits

Few foods naturally contain D₃ (fatty fish, egg yolks, liver). Even with fortification, dietary intake rarely exceeds 200–400 IU/day — far below the ~3,000 IU a fair-skinned person generates with 20 minutes of midday summer sun.

Step 2

The Hydroxylation Cascade

Vitamin D₃ is biologically inert. It must be activated through two sequential hydroxylation steps — first in the liver (CYP2R1 enzyme adds -OH at position 25), then in the kidney (CYP27B1 adds -OH at position 1) — to become the potent hormone calcitriol [1,25(OH)₂D].

Activation Cascade

D₃ Cholecalciferol
LIVER · CYP2R1 +OH at C-25
25(OH)D Calcidiol · BIOMARKER
KIDNEY · CYP27B1 +OH at C-1
1,25(OH)₂D ⚡ Calcitriol · ACTIVE
Why 25(OH)D is the Clinical Biomarker: Calcidiol [25(OH)D] has a half-life of ~2–3 weeks, making it a stable indicator of vitamin D status. Calcitriol's half-life is only 4–6 hours and is tightly regulated — making it unreliable for assessing body stores.
Deficient: <20 ng/mL Insufficient: 20–30 ng/mL Sufficient: >30 ng/mL
Key Insight: Immune cells (macrophages) also express CYP27B1 — allowing local activation of vitamin D without the kidney, on-demand when pathogens are detected. This is the foundation of the macrophage autocrine loop (Step 5).
Step 3

VDR Nuclear Signaling

Calcitriol is a nuclear hormone. As a fat-soluble molecule, it diffuses freely through cell membranes. Inside the cell, it binds the Vitamin D Receptor (VDR), which recruits a co-receptor (RXR) to form a heterodimer. This complex enters the nucleus and binds Vitamin D Response Elements (VDREs) in DNA, directly activating gene transcription.

Membrane Diffusion

Calcitriol diffuses through the plasma membrane (lipophilic — no transporter needed).

VDR Binding

Binds Vitamin D Receptor (VDR) → conformational change in receptor structure.

Heterodimer Formation

VDR recruits co-receptor RXR → VDR:RXR heterodimer forms.

Nuclear Translocation

Complex translocates to nucleus, binds VDRE sequences on target genes.

Transcription Activated — Gene Products

Cathelicidin (CAMP) · β-Defensin 2 (DEFB4) · CYP24A1 (feedback degradation) · IL-10 (anti-inflammatory)

Why This Matters: VDR Is Everywhere
The VDR is expressed in over 30 different tissue types, including nearly every cell of the immune system — monocytes, macrophages, dendritic cells, T cells, and B cells. Genome-wide studies have identified 2,776 VDR binding sites (VDREs) across the human genome, influencing the expression of ~229 genes. This makes vitamin D one of the most pleiotropic hormones in human biology.
Innate Defense

Nature's Antibiotics

The most potent immune output of vitamin D signaling: antimicrobial peptides (AMPs). Cathelicidin (LL-37) and β-defensins are gene products directly induced by VDR signaling. They work by inserting themselves into the lipid membranes of bacteria and fungi, forming pores that cause ion leakage and membrane depolarization — physically destroying the invader.

⚔️ LL-37: Dual Agent

Cathelicidin LL-37 doesn't just kill bacteria. It also acts as an immunomodulatory signal — it recruits neutrophils and monocytes to the infection site (chemotaxis), promotes wound healing, and can even neutralize bacterial endotoxin (LPS). Its expression is almost entirely dependent on vitamin D — the CAMP gene promoter contains a potent VDRE that is one of the most robustly regulated vitamin D target genes known.

🔬 The Tuberculosis Connection

Before antibiotics, TB patients were treated with sunlight therapy (heliotherapy) in sanatoriums — and it worked. The mechanism was unknown until 2006, when Liu et al. published in Science that TLR activation in macrophages upregulates the vitamin D–cathelicidin pathway, directly killing M. tuberculosis. This landmark paper provided the first molecular explanation for why sunlight helps fight TB, and why vitamin D deficiency is a risk factor for the disease.

Critical Mechanism

The Macrophage Autocrine Loop

The pivotal discovery: macrophages don't wait for the kidney. When they detect a pathogen (via TLR2/1 recognition of PAMPs), they upregulate both VDR expression and CYP27B1 — the activating enzyme. If sufficient circulating 25(OH)D is available as substrate, the macrophage converts it to calcitriol locally, on-demand, producing its own cathelicidin. This autocrine loop is the strongest mechanistic link between vitamin D status and infection defense.

Pathogen Detected

TLR2/1 on macrophage surface recognizes pathogen-associated molecular patterns (PAMPs) — e.g., lipopeptides from M. tuberculosis cell wall.

Gene Upregulation

TLR signaling drives: ↑ CYP27B1 (the 1α-hydroxylase enzyme) and ↑ VDR expression. The macrophage primes itself to respond to vitamin D.

Local Activation

Circulating 25(OH)D from serum enters the macrophage and is converted to 1,25(OH)₂D (calcitriol) by CYP27B1 — entirely within the cell, bypassing the kidney.

Cathelicidin Produced → Pathogen Killed 🎯

Local calcitriol activates VDR → VDRE on CAMP gene → cathelicidin (LL-37) produced → pathogen membrane disrupted and killed.

Why Serum Levels Predict Immune Function:
"Macrophages need circulating 25(OH)D as substrate. This is why serum levels predict immune function." If 25(OH)D is depleted at baseline, the macrophage cannot complete step ③ — the entire loop stalls regardless of TLR activation or VDR upregulation.

Liu et al. (2006) — The Landmark Paper in Science

Published in Science, this study demonstrated that TLR2/1 activation of human macrophages by M. tuberculosis upregulated both VDR and CYP27B1 expression. When sufficient 25(OH)D was available, the macrophages converted it to calcitriol locally, induced cathelicidin, and killed the intracellular bacteria. Critically, when researchers used serum from African-American donors (who had lower 25(OH)D levels on average), the macrophages could NOT generate enough cathelicidin to kill TB — directly linking serum vitamin D status to innate antimicrobial capacity.

Adaptive Immunity

Rebalancing the T-Cell Response

Vitamin D doesn't just boost innate immunity — it actively rebalances adaptive immunity. It promotes tolerogenic dendritic cells and shifts T-cell differentiation: suppressing pro-inflammatory Th1 and Th17 subsets while promoting regulatory T cells (Treg) and Th2 responses.

Deficient — Pro-Inflammatory Dominance

Th1 ↑↑
IFN-γ — pro-inflammatory
Th17 ↑↑
IL-17 — autoimmune risk
Th2 →
IL-4 — neutral
Treg →
IL-10 — minimal

Sufficient — Regulatory Balance Restored

Th1 ↓
IFN-γ — suppressed
Th17 ↓
IL-17 — suppressed
Th2 ↑
IL-4 — enhanced
Treg ↑↑
IL-10 — promoted
Subset Deficient State Sufficient State
Th1 ↑↑ pro-inflammatory (IFN-γ) ↓ suppressed
Th17 ↑↑ autoimmune risk (IL-17) ↓ suppressed
Th2 → neutral ↑ enhanced (IL-4)
Treg → minimal ↑↑ promoted (IL-10)

🌪️ Why This Prevents Cytokine Storms

In severe infections (COVID-19, sepsis), unchecked Th1/Th17 responses produce a "cytokine storm" — a flood of IL-6, TNF-α, and IL-17 that damages host tissue more than the pathogen does. Vitamin D's ability to dampen this overreaction while maintaining pathogen defense via innate immunity (cathelicidin) is what makes it uniquely protective against severe outcomes.

🛡️ Autoimmune Implications

The promotion of Treg cells and tolerogenic dendritic cells explains vitamin D's association with reduced autoimmune disease risk. The VITAL trial showed a 22% reduction in autoimmune disease with vitamin D supplementation over 5.3 years — one of the most robust findings in the entire vitamin D literature.

Barrier Function

Fortifying Epithelial Barriers

Beyond immune cells, vitamin D strengthens the physical barriers that pathogens must cross — respiratory and gut epithelia. It upregulates tight junction proteins (occludin, claudin-1, claudin-4) that seal the gaps between epithelial cells, reducing pathogen entry.

🦠 Pathogens — breaching gaps
Epithelial cells — tight junctions ABSENT / WEAK
⬇ Pathogens cross into subepithelial tissue
Inflammatory infiltrate — tissue damage, systemic response
🦠 Pathogens — BLOCKED at surface
Epithelial cells — Occludin · Claudin-1 · Claudin-4 expressed ✓
+ Antimicrobial peptides secreted into airway surface liquid
Intact barrier — pathogens cleared at surface

🫁 Respiratory Epithelium

The airways are the primary entry point for respiratory pathogens. Vitamin D enhances the expression of tight junction proteins and promotes secretion of antimicrobial peptides into the airway surface liquid. This creates a dual physical-chemical barrier critical for preventing viral entry — particularly relevant for SARS-CoV-2, influenza, and RSV infections.

🦠 Gut Barrier ("Leaky Gut")

Vitamin D deficiency is associated with increased intestinal permeability. The VDR directly regulates expression of claudin-2, -12, and -15 in intestinal epithelium. Compromised gut barrier allows bacterial translocation, contributing to systemic inflammation, endotoxemia, and potentially driving autoimmune conditions like IBD and celiac disease.

Clinical Evidence

Theory Meets Practice

The mechanistic case is compelling. But does supplementation actually reduce infection rates in clinical trials? The answer is nuanced: it depends on who is being treated, how they're dosed, and what their baseline level is.

Protection by Baseline 25(OH)D Level

Risk reduction is inversely proportional to starting 25(OH)D level. The severely deficient benefit enormously; the already-sufficient gain almost nothing.

Severe deficiency (<10 ng/mL) 70% risk reduction
Deficient (10–20 ng/mL) 25% risk reduction
Insufficient (20–30 ng/mL) 8% risk reduction
Sufficient (>30 ng/mL) 2% risk reduction

Based on Martineau et al. (2017) IPD meta-analysis — 25 RCTs, n=11,321

Bolus Dosing Fails — Daily/Weekly Dosing Works

Daily or weekly dosing is protective. Large infrequent bolus doses are consistently not protective — likely because spikes trigger rapid CYP24A1-mediated degradation before stable 25(OH)D elevation is achieved.

Bolus monthly dose ~8% — NOT protective ✗
Daily 800 IU ~15% reduction ✓
Weekly 10,000 IU / Daily 1,000 IU ~19% reduction ✓
Daily 2,000 IU ~25% reduction ✓
Daily 4,000 IU ~30% reduction ✓

Illustrative dose-response trends from Jolliffe et al. (2021)

Respiratory Infections

Daily/weekly dosing reduces acute respiratory infections, especially in the severely deficient (OR 0.30 for <25 nmol/L baseline).

Healthy Populations

Large trials on sufficient, healthy adults (VITAL, n=25,871) show no significant infection reduction. You cannot boost above an already-sufficient baseline.

🔍
COVID-19 Severity

Strong observational correlation: low vitamin D → higher ICU rates. Interventional RCTs are suggestive but not yet definitive for prevention.

📈
Autoimmune Disease

VITAL's 5.3-year follow-up: 22% reduction in autoimmune disease incidence with vitamin D. One of the strongest results in the entire literature.

Study Timeline

2007
Laaksi et al. ✓ Positive

Finnish military recruits: 36% fewer respiratory infections with vitamin D supplementation.

2012
Bergman et al. Meta-analysis ✓ Positive

OR 0.58 for respiratory infections with vitamin D supplementation.

2017
Martineau et al. ✓ Positive

IPD meta-analysis (25 RCTs, n=11,321): 12% overall reduction, 70% in severely deficient.

2019
VITAL (Manson) ✗ Negative

n=25,871 healthy adults: No significant reduction in primary endpoints. Subgroup immune benefit noted. Most participants already sufficient.

2021
Jolliffe et al. ✓ Positive

Updated meta-analysis: confirmed daily/weekly dosing protective; bolus dosing consistently NOT protective.

2022
CORONAVIT ~ Mixed

UK trial: 6% nonsignificant reduction in COVID infection. Severity benefit noted among those testing positive.

2022
VITAL Autoimmune (Hahn) ✓ Positive

5.3yr follow-up: 22% reduction in autoimmune disease incidence with 2,000 IU/day vitamin D.

"Vitamin D is not a magic shield for everyone. It is a critical support system that fails when fuel is low. Correcting deficiency is high-yield; boosting sufficiency is low-yield."

The pattern across all meta-analyses is remarkably consistent: daily dosing in deficient individuals reduces respiratory infections by 40–70% (Martineau 2017; Jolliffe 2021). The same intervention in sufficient individuals produces near-zero benefit (VITAL, Manson 2019). The biology — macrophage autocrine loop, tight junction integrity — explains precisely why.

📚 Scientific References — Summaries & Access

📖 All articles retrieved from peer-reviewed literature · DOI links provided for each reference · Proper attribution required per terms of use
1
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data ✓ Positive IPD Meta-analysis (25 RCTs, n=11,321)
Martineau AR et al. · BMJ. 2017;356:i6583 · doi:10.1136/bmj.i6583
2
Vitamin D supplementation to prevent acute respiratory infections ✓ Positive Aggregate RCT Meta-analysis
Jolliffe DA et al. · Lancet Diabetes Endocrinol. 2021;9(5):276-292 · doi:10.1016/S2213-8587(21)00051-6
3
Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response ⚗ Mechanistic In vitro mechanistic study
Liu PT et al. · Science. 2006;311(5768):1770-1773 · doi:10.1126/science.1123933
4
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL Trial) ✗ Null Result Large RCT (n=25,871, 5.3 years)
Manson JE et al. · NEJM. 2019;380(1):33-44 · doi:10.1056/NEJMoa1809944
5
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial ✓ Positive RCT extended follow-up (5.3 years)
Hahn J et al. · BMJ. 2022;376:e066452 · doi:10.1136/bmj-2021-066452
6
Vitamin D and the immune system ⚗ Mechanistic Review article
Aranow C · J Investig Med. 2011;59(6):881-886 · doi:10.2310/JIM.0b013e31821b8755
7
Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity ⚗ Mechanistic Review article
Adams JS, Hewison M · Nat Clin Pract Endocrinol Metab. 2008;4(2):80-90
8
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and COVID-19 (CORONAVIT) ~ Mixed RCT (COVID-19 era, UK)
Jolliffe DA et al. · BMJ. 2022;378:e071230

This page is for educational purposes only and does not constitute medical advice. All claims are grounded in peer-reviewed literature. Supplementation decisions should be made in consultation with a qualified healthcare provider. Serum 25(OH)D testing is available through standard clinical laboratories.